Identification of gene signatures regulated by carvedilol in mouse heart

Jian Peng Teoh, Kyoung Mi Park, Zuzana Broskova, Felix R. Jimenez, Ahmed S. Bayoumi, Krystal Archer, Huabo Su, John Johnson, Neal L. Weintraub, Yaoliang Tang, Il Man Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Chronic treatment with the β-blocker carvedilol has been shown to reduce established maladaptive left ventricle (LV) hypertrophy and to improve LV function in experimental heart failure. However, the detailed mechanisms by which carvedilol improves LV failure are incompletely understood. We previously showed that carvedilol is a β-arrestinbiased β1-adrenergic receptor ligand, which activates cellular pathways in the heart independent of G protein-mediated second messenger signaling. More recently, we have demonstrated by microRNA (miR) microarray analysis that carvedilol upregulates a subset of mature and pre-mature miRs, but not their primary miR transcripts in mouse hearts. Here, we next sought to identify the effects of carvedilol on LV gene expression on a genome-wide basis. Adult mice were treated with carvedilol or vehicle for 1 wk. RNA was isolated from LV tissue and hybridized for microarray analysis. Gene expression profiling analysis revealed a small group of genes differentially expressed after carvedilol treatment. Further analysis categorized these genes into pathways involved in tight junction, malaria, viral myocarditis, glycosaminoglycan biosynthesis, and arrhythmogenic right ventricular cardiomyopathy. Genes encoding proteins in the tight junction, malaria, and viral myocarditis pathways were upregulated in the LV by carvedilol, while genes encoding proteins in the glycosaminoglycan biosynthesis and arrhythmogenic right ventricular cardiomyopathy pathways were downregulated by carvedilol. These gene expression changes may reflect the molecular mechanisms that underlie the functional benefits of carvedilol therapy.

Original languageEnglish (US)
Pages (from-to)376-385
Number of pages10
JournalPhysiological Genomics
Volume47
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

Heart Ventricles
Genes
Arrhythmogenic Right Ventricular Dysplasia
Tight Junctions
Myocarditis
Glycosaminoglycans
MicroRNAs
Malaria
carvedilol
Tissue Array Analysis
Gene Expression
Second Messenger Systems
Gene Expression Profiling
Microarray Analysis
GTP-Binding Proteins
Adrenergic Receptors
Hypertrophy
Proteins
Up-Regulation
Down-Regulation

Keywords

  • Beta-blocker
  • Biased G protein-coupled receptor signaling
  • Gene regulation
  • Left ventricle
  • Transcriptome

ASJC Scopus subject areas

  • Physiology
  • Genetics

Cite this

Teoh, J. P., Park, K. M., Broskova, Z., Jimenez, F. R., Bayoumi, A. S., Archer, K., ... Kim, I. M. (2015). Identification of gene signatures regulated by carvedilol in mouse heart. Physiological Genomics, 47(9), 376-385. https://doi.org/10.1152/physiolgenomics.00028.2015

Identification of gene signatures regulated by carvedilol in mouse heart. / Teoh, Jian Peng; Park, Kyoung Mi; Broskova, Zuzana; Jimenez, Felix R.; Bayoumi, Ahmed S.; Archer, Krystal; Su, Huabo; Johnson, John; Weintraub, Neal L.; Tang, Yaoliang; Kim, Il Man.

In: Physiological Genomics, Vol. 47, No. 9, 01.09.2015, p. 376-385.

Research output: Contribution to journalArticle

Teoh JP, Park KM, Broskova Z, Jimenez FR, Bayoumi AS, Archer K et al. Identification of gene signatures regulated by carvedilol in mouse heart. Physiological Genomics. 2015 Sep 1;47(9):376-385. https://doi.org/10.1152/physiolgenomics.00028.2015
Teoh, Jian Peng ; Park, Kyoung Mi ; Broskova, Zuzana ; Jimenez, Felix R. ; Bayoumi, Ahmed S. ; Archer, Krystal ; Su, Huabo ; Johnson, John ; Weintraub, Neal L. ; Tang, Yaoliang ; Kim, Il Man. / Identification of gene signatures regulated by carvedilol in mouse heart. In: Physiological Genomics. 2015 ; Vol. 47, No. 9. pp. 376-385.
@article{db7ec5dc74fe498f9dfcb9bcd7cc53a0,
title = "Identification of gene signatures regulated by carvedilol in mouse heart",
abstract = "Chronic treatment with the β-blocker carvedilol has been shown to reduce established maladaptive left ventricle (LV) hypertrophy and to improve LV function in experimental heart failure. However, the detailed mechanisms by which carvedilol improves LV failure are incompletely understood. We previously showed that carvedilol is a β-arrestinbiased β1-adrenergic receptor ligand, which activates cellular pathways in the heart independent of G protein-mediated second messenger signaling. More recently, we have demonstrated by microRNA (miR) microarray analysis that carvedilol upregulates a subset of mature and pre-mature miRs, but not their primary miR transcripts in mouse hearts. Here, we next sought to identify the effects of carvedilol on LV gene expression on a genome-wide basis. Adult mice were treated with carvedilol or vehicle for 1 wk. RNA was isolated from LV tissue and hybridized for microarray analysis. Gene expression profiling analysis revealed a small group of genes differentially expressed after carvedilol treatment. Further analysis categorized these genes into pathways involved in tight junction, malaria, viral myocarditis, glycosaminoglycan biosynthesis, and arrhythmogenic right ventricular cardiomyopathy. Genes encoding proteins in the tight junction, malaria, and viral myocarditis pathways were upregulated in the LV by carvedilol, while genes encoding proteins in the glycosaminoglycan biosynthesis and arrhythmogenic right ventricular cardiomyopathy pathways were downregulated by carvedilol. These gene expression changes may reflect the molecular mechanisms that underlie the functional benefits of carvedilol therapy.",
keywords = "Beta-blocker, Biased G protein-coupled receptor signaling, Gene regulation, Left ventricle, Transcriptome",
author = "Teoh, {Jian Peng} and Park, {Kyoung Mi} and Zuzana Broskova and Jimenez, {Felix R.} and Bayoumi, {Ahmed S.} and Krystal Archer and Huabo Su and John Johnson and Weintraub, {Neal L.} and Yaoliang Tang and Kim, {Il Man}",
year = "2015",
month = "9",
day = "1",
doi = "10.1152/physiolgenomics.00028.2015",
language = "English (US)",
volume = "47",
pages = "376--385",
journal = "Physiological Genomics",
issn = "1094-8341",
publisher = "American Physiological Society",
number = "9",

}

TY - JOUR

T1 - Identification of gene signatures regulated by carvedilol in mouse heart

AU - Teoh, Jian Peng

AU - Park, Kyoung Mi

AU - Broskova, Zuzana

AU - Jimenez, Felix R.

AU - Bayoumi, Ahmed S.

AU - Archer, Krystal

AU - Su, Huabo

AU - Johnson, John

AU - Weintraub, Neal L.

AU - Tang, Yaoliang

AU - Kim, Il Man

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Chronic treatment with the β-blocker carvedilol has been shown to reduce established maladaptive left ventricle (LV) hypertrophy and to improve LV function in experimental heart failure. However, the detailed mechanisms by which carvedilol improves LV failure are incompletely understood. We previously showed that carvedilol is a β-arrestinbiased β1-adrenergic receptor ligand, which activates cellular pathways in the heart independent of G protein-mediated second messenger signaling. More recently, we have demonstrated by microRNA (miR) microarray analysis that carvedilol upregulates a subset of mature and pre-mature miRs, but not their primary miR transcripts in mouse hearts. Here, we next sought to identify the effects of carvedilol on LV gene expression on a genome-wide basis. Adult mice were treated with carvedilol or vehicle for 1 wk. RNA was isolated from LV tissue and hybridized for microarray analysis. Gene expression profiling analysis revealed a small group of genes differentially expressed after carvedilol treatment. Further analysis categorized these genes into pathways involved in tight junction, malaria, viral myocarditis, glycosaminoglycan biosynthesis, and arrhythmogenic right ventricular cardiomyopathy. Genes encoding proteins in the tight junction, malaria, and viral myocarditis pathways were upregulated in the LV by carvedilol, while genes encoding proteins in the glycosaminoglycan biosynthesis and arrhythmogenic right ventricular cardiomyopathy pathways were downregulated by carvedilol. These gene expression changes may reflect the molecular mechanisms that underlie the functional benefits of carvedilol therapy.

AB - Chronic treatment with the β-blocker carvedilol has been shown to reduce established maladaptive left ventricle (LV) hypertrophy and to improve LV function in experimental heart failure. However, the detailed mechanisms by which carvedilol improves LV failure are incompletely understood. We previously showed that carvedilol is a β-arrestinbiased β1-adrenergic receptor ligand, which activates cellular pathways in the heart independent of G protein-mediated second messenger signaling. More recently, we have demonstrated by microRNA (miR) microarray analysis that carvedilol upregulates a subset of mature and pre-mature miRs, but not their primary miR transcripts in mouse hearts. Here, we next sought to identify the effects of carvedilol on LV gene expression on a genome-wide basis. Adult mice were treated with carvedilol or vehicle for 1 wk. RNA was isolated from LV tissue and hybridized for microarray analysis. Gene expression profiling analysis revealed a small group of genes differentially expressed after carvedilol treatment. Further analysis categorized these genes into pathways involved in tight junction, malaria, viral myocarditis, glycosaminoglycan biosynthesis, and arrhythmogenic right ventricular cardiomyopathy. Genes encoding proteins in the tight junction, malaria, and viral myocarditis pathways were upregulated in the LV by carvedilol, while genes encoding proteins in the glycosaminoglycan biosynthesis and arrhythmogenic right ventricular cardiomyopathy pathways were downregulated by carvedilol. These gene expression changes may reflect the molecular mechanisms that underlie the functional benefits of carvedilol therapy.

KW - Beta-blocker

KW - Biased G protein-coupled receptor signaling

KW - Gene regulation

KW - Left ventricle

KW - Transcriptome

UR - http://www.scopus.com/inward/record.url?scp=84940742699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940742699&partnerID=8YFLogxK

U2 - 10.1152/physiolgenomics.00028.2015

DO - 10.1152/physiolgenomics.00028.2015

M3 - Article

C2 - 26152686

AN - SCOPUS:84940742699

VL - 47

SP - 376

EP - 385

JO - Physiological Genomics

JF - Physiological Genomics

SN - 1094-8341

IS - 9

ER -